ECS (ASX) Are we there .....

Originally posted by wolfk: ↑

If you want some ECS positivity. Just look up Murray Sherbert and Green Gelato on Reddit. The UK medicinal cannabis thread is exceptionally fond of it, they look to have re-stocked in the past week or so. But the descriptions and reviews are near-all positive. When people say that their prescriber recommends an ECS product, you can’t complain. Alongside ECS not having to put in any of the laborious education of prescribers and advertising that comes with selling own brands.

And it seems although we market as a premium flower, people indicate that it’s around £5.5/g in a 30g pouch (from Curaleaf). Which is about £0.8 more than the cheapest on the market. Many others are selling around the £8-9 mark. So buyers are stating that ECS is a great ‘value’ product. Regardless, the product is out there, it’s high quality and being well received. Under the banner of Curaleaf none the less, likely one of, if the most reputable global brand (~$4.4b AUD market cap). If anyone is to acquire a $20m market cap sized grower to diversify their regional range, it’s them. If someone else like Bloomwell doesn’t do it first.

Again, I am so unbelievably bullish on ECS and we are well and truly present in the global market. Once people find a strain they find beneficial and therapeutic, they want to stay with it. Demand grows, ECS demand grows and so on, you know the story. I suspect the Amnesia Haze that we recently had TGA export approval will soon hit the shelves, potentially for Ilios Sante, which will give the exposure to the rapidly expanding German market. I am honestly not sure how ECS plans on being able to scale up quick enough. There are definitely worse positions to be in than having our product in too much demand.

Expand

Green Gelato script here in Oz. Thumbs up here.

Originally posted by wolfk: ↑

If you want some ECS positivity. Just look up Murray Sherbert and Green Gelato on Reddit. The UK medicinal cannabis thread is exceptionally fond of it, they look to have re-stocked in the past week or so. But the descriptions and reviews are near-all positive. When people say that their prescriber recommends an ECS product, you can’t complain. Alongside ECS not having to put in any of the laborious education of prescribers and advertising that comes with selling own brands.

And it seems although we market as a premium flower, people indicate that it’s around £5.5/g in a 30g pouch (from Curaleaf). Which is about £0.8 more than the cheapest on the market. Many others are selling around the £8-9 mark. So buyers are stating that ECS is a great ‘value’ product. Regardless, the product is out there, it’s high quality and being well received. Under the banner of Curaleaf none the less, likely one of, if the most reputable global brand (~$4.4b AUD market cap). If anyone is to acquire a $20m market cap sized grower to diversify their regional range, it’s them. If someone else like Bloomwell doesn’t do it first.

Again, I am so unbelievably bullish on ECS and we are well and truly present in the global market. Once people find a strain they find beneficial and therapeutic, they want to stay with it. Demand grows, ECS demand grows and so on, you know the story. I suspect the Amnesia Haze that we recently had TGA export approval will soon hit the shelves, potentially for Ilios Sante, which will give the exposure to the rapidly expanding German market. I am honestly not sure how ECS plans on being able to scale up quick enough. There are definitely worse positions to be in than having our product in too much demand.

Expand

No.	Vol.	Price($)
7	3834000	1.7¢

No.

Vol.

Price($)

3834000

1.7¢

Price($)	Vol.	No.
1.8¢	856757	1

Price($)

Vol.

No.

1.8¢

856757

No.	Vol.	Price($)
6	3334000	0.017
14	4131596	0.016
9	1792232	0.015
4	1122094	0.014
6	679561	0.013

No.

Vol.

Price($)

3334000

0.017

4131596

0.016

1792232

0.015

1122094

0.014

679561

0.013

Price($)	Vol.	No.
0.018	856757	1
0.019	3252724	4
0.020	546158	6
0.021	1222157	5
0.022	752190	5

Price($)

Vol.

No.

0.018

856757

0.019

3252724

0.020

546158

0.021

1222157

0.022

752190

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $23.19M

Open	High	Low	Value	Volume
1.8¢	1.8¢	1.8¢	$21.58K	1.199M

Are we there ....., page-16

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Are we there ....., page-16

Top Stories

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News